These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29648602)

  • 1. Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection.
    Wang Y; Guo Q; Yan Z; Zhou D; Zhang W; Zhou S; Li YP; Yuan J; Uyeki TM; Shen X; Wu W; Zhao H; Wu YF; Shang J; He Z; Yang Y; Zhao H; Hong Y; Zhang Z; Wu M; Wei T; Deng X; Deng Y; Cai LH; Lu W; Shu H; Zhang L; Luo H; Ing Zhou Y; Weng H; Song K; Yao L; Jiang M; Zhao B; Chi R; Guo B; Fu L; Yu L; Min H; Chen P; Chen S; Hong L; Mao W; Huang X; Gu L; Li H; Wang C; Cao B;
    J Infect Dis; 2018 May; 217(11):1708-1717. PubMed ID: 29648602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients With Avian Influenza A(H7N9) Virus.
    Zheng S; Tang L; Gao H; Wang Y; Yu F; Cui D; Xie G; Yang X; Zhang W; Ye X; Zhang Z; Wang X; Yu L; Zhang Y; Yang S; Liang W; Chen Y; Li L
    Clin Infect Dis; 2018 Mar; 66(7):1054-1060. PubMed ID: 29077848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology of human influenza A(H7N9) infection in Hong Kong.
    Leung YH; To MK; Lam TS; Yau SW; Leung OS; Chuang SK
    J Microbiol Immunol Infect; 2017 Apr; 50(2):183-188. PubMed ID: 26220305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study.
    Zhang Y; Gao H; Liang W; Tang L; Yang Y; Wu X; Yu L; Chen P; Zheng S; Ou H; Li L
    BMC Infect Dis; 2016 Feb; 16():76. PubMed ID: 26864456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly pathogenic avian influenza H7N9 viruses with reduced susceptibility to neuraminidase inhibitors showed comparable replication capacity to their sensitive counterparts.
    Tang J; Zhang J; Zhou J; Zhu W; Yang L; Zou S; Wei H; Xin L; Huang W; Li X; Cheng Y; Wang D
    Virol J; 2019 Jul; 16(1):87. PubMed ID: 31266524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of viral genomic mutations in novel influenza A (H7N9)-infected patients: the association between oseltamivir-resistant variants and viral shedding duration.
    Chen R; Zou Q; Xie G; Yu F; Yang X; Cao L; Huo Z; Zheng S
    Virus Genes; 2019 Oct; 55(5):592-599. PubMed ID: 31302878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant Corticosteroid Treatment in Adults With Influenza A (H7N9) Viral Pneumonia.
    Cao B; Gao H; Zhou B; Deng X; Hu C; Deng C; Lu H; Li Y; Gan J; Liu J; Li H; Zhang Y; Yang Y; Fang Q; Shen Y; Gu Q; Zhou X; Zhao W; Pu Z; Chen L; Sun B; Liu X; Hamilton CD; Li L
    Crit Care Med; 2016 Jun; 44(6):e318-28. PubMed ID: 26934144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extra-pulmonary viral shedding in H7N9 Avian Influenza patients.
    Zhu Z; Liu Y; Xu L; Guan W; Zhang X; Qi T; Shi B; Song Z; Liu X; Wan Y; Tian D; He J; Zhang X; Wu M; Lu H; Lu S; Zhang Z; Yuan Z; Hu Y
    J Clin Virol; 2015 Aug; 69():30-2. PubMed ID: 26209373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance.
    Hu Y; Lu S; Song Z; Wang W; Hao P; Li J; Zhang X; Yen HL; Shi B; Li T; Guan W; Xu L; Liu Y; Wang S; Zhang X; Tian D; Zhu Z; He J; Huang K; Chen H; Zheng L; Li X; Ping J; Kang B; Xi X; Zha L; Li Y; Zhang Z; Peiris M; Yuan Z
    Lancet; 2013 Jun; 381(9885):2273-9. PubMed ID: 23726392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.
    Marjuki H; Mishin VP; Chesnokov AP; Jones J; De La Cruz JA; Sleeman K; Tamura D; Nguyen HT; Wu HS; Chang FY; Liu MT; Fry AM; Cox NJ; Villanueva JM; Davis CT; Gubareva LV
    J Infect Dis; 2015 Jan; 211(2):249-57. PubMed ID: 25124927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China.
    Yu H; Liao Q; Yuan Y; Zhou L; Xiang N; Huai Y; Guo X; Zheng Y; van Doorn HR; Farrar J; Gao Z; Feng Z; Wang Y; Yang W
    BMJ; 2010 Sep; 341():c4779. PubMed ID: 20876641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of viral shedding of influenza A (H1N1) virus infection treated with oseltamivir and/or traditional Chinese medicine in China: a retrospective analysis.
    Wang YG; Jiang M; Wang RB; Zha QL; Zhang SJ; Zhou GQ; Li XW; Wang YY; Lv AP
    J Tradit Chin Med; 2012 Jun; 32(2):148-55. PubMed ID: 22876436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors promoting the prolonged shedding of the pandemic (H1N1) 2009 influenza virus in patients treated with oseltamivir for 5 days.
    Ryoo SM; Kim WY; Sohn CH; Seo DW; Oh BJ; Lee JH; Lee YS; Lim KS
    Influenza Other Respir Viruses; 2013 Sep; 7(5):833-7. PubMed ID: 23279949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.
    Marjuki H; Mishin VP; Chesnokov AP; De La Cruz JA; Davis CT; Villanueva JM; Fry AM; Gubareva LV
    J Virol; 2015 May; 89(10):5419-26. PubMed ID: 25740997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between human infections caused by highly and low pathogenic H7N9 avian influenza viruses in Wave Five: Clinical and virological findings.
    Yang Y; Wong G; Yang L; Tan S; Li J; Bai B; Xu Z; Li H; Xu W; Zhao X; Quan C; Zheng H; Liu WJ; Liu W; Liu L; Liu Y; Bi Y; Gao GF
    J Infect; 2019 Mar; 78(3):241-248. PubMed ID: 30664912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza A-associated severe pneumonia in hospitalized patients: Risk factors and NAI treatments.
    Zou Q; Zheng S; Wang X; Liu S; Bao J; Yu F; Wu W; Wang X; Shen B; Zhou T; Zhao Z; Wang Y; Chen R; Wang W; Ma J; Li Y; Wu X; Shen W; Xie F; Vijaykrishna D; Chen Y
    Int J Infect Dis; 2020 Mar; 92():208-213. PubMed ID: 31978583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substitution of I222L-E119V in neuraminidase from highly pathogenic avian influenza H7N9 virus exhibited synergistic resistance effect to oseltamivir in mice.
    Tang J; Gao R; Liu L; Zhang S; Liu J; Li X; Fang Q; Feng Z; Xu C; Huang W; Wang D
    Sci Rep; 2021 Aug; 11(1):16293. PubMed ID: 34381119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary Epidemiology of Human Infections with Highly Pathogenic Avian Influenza A(H7N9) Virus, China, 2017.
    Zhou L; Tan Y; Kang M; Liu F; Ren R; Wang Y; Chen T; Yang Y; Li C; Wu J; Zhang H; Li D; Greene CM; Zhou S; Iuliano AD; Havers F; Ni D; Wang D; Feng Z; Uyeki TM; Li Q
    Emerg Infect Dis; 2017 Aug; 23(8):1355-1359. PubMed ID: 28580900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a quadruple qRT-PCR assay for simultaneous identification of highly and low pathogenic H7N9 avian influenza viruses and characterization against oseltamivir resistance.
    Yang Y; Li S; Wong G; Ma S; Xu Z; Zhao X; Li H; Xu W; Zheng H; Lin J; Zhao Q; Liu W; Liu Y; Gao GF; Bi Y
    BMC Infect Dis; 2018 Aug; 18(1):406. PubMed ID: 30111290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.